Trillium Therapeutics Inc (TRIL)

[NY1972]

TRIL took a lot of hits for on target tox. TTI621 is the only anti CD47 that works mono/combo, AML complete molecular remission, TTI-621/rituximab combination obtained robust lymphoma regressions.

Has 90002 shown a PR in 2 years??
"low dose tox pretty high. How will an even safer low dose reach tissue from non-blood cancers? Maybe $CELG #CD47 drug is the answer?"

$TRIL low dose tox pretty high. How will an even safer low dose reach tissue from non-blood cancers? Maybe $CELG #CD47 drug is the answer?

— Anthony Schwartz, PhD (@aschwartzphd) December 1, 2016